Examination of HDAC1,2 selective inhibitors in clinical trials is warranted, in combination with doxorubicin or other therapeutics with the potential advantage that chemoresistance in the refractory EZH2GOF DLBCL may be mitigated to trigger increased cell death. Here, HDAC1 is linked to diffuse large B-cell lymphoma.